iwCLL Program
| Friday, 20 September | ||
|---|---|---|
| 7:30 – 16:30 |
Young Investigator Meeting | |
| 19:00 – 21:00 | iwCLL Welcome Reception at the Edinburgh Castle |
|
| Saturday, 21 September | ||
|---|---|---|
| 08:15 | Welcome and Introductions Opening Remarks Peter Hillmen |
|
| 08:30 | History of CLL Gerald Marti |
|
| THEME 1: BIOLOGY AND PATHOPHYSIOLOGY | ||
| Session 1: |
The CLL (Epi)genome | |
| 08:45 | Overview of the CLL Genome Jonathan Strefford |
|
| 09:05 | The Epigenetic Features of CLL: DNA Methylation Christoph Plass |
|
| 09:25 |
Insights From Tertiary Structure, Chromatin Modifications, and Nuclear Organization José Ignacio Martín-Subero |
|
| 09:45 | Selected Abstracts | |
| 10:15 | Morning Break | |
| Session 2: |
The CLL (Epi)genome (cont.) | |
| 10:45 | Keynote Evolution and Mathematical Modelling of Cancer Genomes Gad Getz |
|
| 11:15 | Functional Implications of Genomic Lesions Catherine Wu |
|
| 11:35 |
The Impact of Regulatory RNA Molecules Marek Mráz |
|
| 11:55 | ATM: Pathway, Lesions, and Targeting Tatjana Stankovic |
|
| 12:15 | Selected Abstracts | |
| 12:45 |
Lunch | |
| Session 3: | The B-Cell Receptor | |
| 13:45 | Role of the B-Cell Receptor in B-Cell Oncogenesis Stefano Casola |
|
| 14:15 |
Dissecting CLL Immunogenetics and Emerging B-Cell Receptor Stereotypes Kostas Stamatopoulos |
|
| 14:35 | CLL-Specific Aspects of B-Cell Receptor Signaling Graham Packham |
|
| 14:55 | Selected Abstracts | |
| 15:25 |
Afternoon Break | |
| Session 4: | Microenvironment and Models of CLL | |
| 15:55 | Linking the Microenvironment With CLL Models Nicholas Chiorazzi |
|
| 16:15 |
In Vitro Modelling of the CLL Microenvironment Alan Ramsay |
|
| 16:35 | Murine and Xenograft Models of CLL Shih-Shih Chen |
|
| 16:55 | PDX Models to Investigate Role of NOTCH1 in Richter Transformation Silvia Deaglio |
|
| 17:15 |
Selected Abstracts | |
| 17:45 | End of day 1 | |
| Sunday, 22 September | ||
|---|---|---|
| THEME 2: INNOVATIONS IN THE ASSESSMENT OF CLL | ||
| Session 1: |
||
| 08:15 | Laboratory Assessment of CLL, Including MRD as an End Point Andrew Rawstron |
|
| 08:35 | Molecular Characterization of CLL Richard Rosenquist Brandell |
|
| 08:55 | Clinical Assessment of CLL Carol Moreno |
|
| 09:15 | Critical Assessment and New Development of Prognostic Scoring Systems Barbara Eichhorst |
|
| 09:35 |
Selected Abstracts | |
| 10:05 | Morning Break | |
| THEME 3: THERAPY | ||
| Session 1: |
Initial Therapy | |
| 10:35 | Early Intervention: Can We Justify It and What End Points Should We Consider? Petra Langerbeins |
|
| 10:55 | Current Initial Treatment of CLL – for Young Patients Florence Cymbalista |
|
| 11:15 | Current Initial Treatment of CLL – for Elderly Patients Valentin Goede |
|
| 11:35 | Treatment of CLL From 2019 Onwards: Overview of Recent Phase 3 Trials TBD |
|
| 12:15 | Selected Abstracts | |
| 12:45 | Lunch | |
| Janssen Oncology supported satellite symposium |
||
| 13:30 | Start Time | |
| 15:00 |
Afternoon Break | |
| Session 2: |
Clonal Evolutions and Resistance Mechanisms |
|
| 15:30 | Overview of Clonal Evolution and Genomic Instability in CLL Daniel Landau |
|
| 15:50 | Development of Resistance to B-Cell Receptor Inhibition Jennifer Woyach |
|
| 16:10 | Development of Resistance to BCL2 Inhibition Mary Ann Anderson |
|
| 16:30 |
Selected Abstracts | |
| 17:15 |
Binet/Rai Medal Presentation | |
| 17:30 |
Poster Session Reception | |
| 19:00 |
End of day 2 | |
| Monday, 23 September | ||
|---|---|---|
| Session 3: |
Therapy of Relapsed/Refractory CLL | |
| 08:15 | B-Cell Receptor-Inhibitor Therapy in Relapsed/ Refractory Disease Susan O’Brien |
|
| 08:35 | BCL2-Inhibitor-Based Therapy and MRD in Relapsed/Refractory Disease John Seymour |
|
| 08:55 | Novel Combinations and MRD in Relapsed/ Refractory Disease Matthew Davids |
|
| 09:15 | Defining Duration of Therapy: Is There a Role for MRD? Talha Munir |
|
| 09:35 |
Selected Abstracts | |
| 10:05 |
Morning Break | |
| 10:35 | Evolution of Small Molecule Inhibitors: New vs Old John Byrd |
|
| 10:55 | Updates on Immune Therapy Strategies, Including CAR T-Cell Therapy and Stem Cell Transplant Katy Rezvani |
|
| 11:15 |
Selected Abstracts | |
| 11:45 | Debate: Future Management of CLL: Is There a Role for Cellular Therapy? Moderator: Anna Schuh David Maloney (CAR T) Johannes Schetelig (SCT) Matt Davids (Novel-Novel) |
|
| 12:30 |
Lunch | |
| Session 4: |
Real-World Data and Registries | |
| 13:15 | CLL Clinical Genomics: Overview of the National Programmes in Sweden, the US, the UK, and France Anna Schuh |
|
| 13:30 | Geographic Diversity and Management of CLL in South American Patients Carlos Sérgio Chiattone |
|
| 13:45 | Geographic Diversity and Management of CLL in African Patients Norah Akinola |
|
| 14:00 | Geographic Diversity and Management of CLL in Indian Patients Abraham Varghese |
|
| 14:15 | Geographic Diversity and Management of CLL in Chinese Patients Shenmiao Yang |
|
| 14:30 |
Selected Abstracts | |
| 14:45 |
Afternoon Break | |
| iwCLL UPDATES Chair: Peter Hillmen |
||
| 15:15 | Current Efforts From European and US Real-World Data Christopher Fox (EU) and Anthony Mato (US) |
|
| 15:45 | An Update From the European Research Initiative on CLL (ERIC) Paolo Ghia |
|
| 16:15 |
Reorganization of the iwCLL Michael Hallek |
|
| 16:45 |
Closing Comments Peter Hillmen |
|
| 17:00 | Close of Workshop | |
– Agenda subject to change